Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from June 9, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 7, 2026 — +13.8% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$39.00 – $40.95Entry zone — fair-value band

$40.96Published — price the day we called it

$44.48Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$46.60Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 13 days.

At window close

+13.8%

realized, from the publication price to the last close inside the window

Peak gain

+25.7%

peak, from the publication price — not a realized return

S&P 500, same window

+4.8%

SPY over the identical days, dividend-adjusted

Window close

$46.60

last close inside the window, ended September 7, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published June 9, 2026

Predicted growth

+10%

over the measurement window

Target price

$44.48

the price the thesis aimed for

Entry zone

$39.00 – $40.95

the fair-value band we waited for

Price at publication

$40.96

published June 9, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is a steady healthcare name that can hold up when markets are choppy. A new version of Rybelsus in Canada shows the company is keeping its product plans on track, and demand for diabetes and obesity treatments remains strong. The stock looks reasonably priced for its profit margins, but a recent earnings shortfall and debt levels make the short-term outlook cautious rather than aggressive.

Primary drivers

New Rybelsus version in Canada keeps product plans moving
Ongoing strong demand for diabetes and obesity drugs
Lower-risk healthcare exposure helps in volatile markets
Reasonable price versus high margins helps limit downside

How it played out

NVO: target reached in 13 days

Lyra published NVO at 40.96 with a 10% short-term growth thesis and a 44.48 target. The thesis pointed to a new Rybelsus version in Canada, strong demand for diabetes and obesity treatments, defensive healthcare exposure in volatile markets, and a reasonable price relative to margins. It also noted a recent earnings shortfall and debt, so the outlook was cautious.

The target was reached in 13 days. NVO peaked at 51.46 on 2026-07-29, a 25.7% gain, then ended the window at 46.60. The published thesis played out and exceeded its stated objective.

What happened during the window

On July 15, 2026, Novo Nordisk announced European Commission approval of the Wegovy pill for weight management. On August 4, 2026, the company reported its second-quarter results and raised its full-year adjusted sales and operating profit outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals